JNCCN 360 - jNCCN360Search

Your search results for Vanessa A. Carter, BS

Lisocabtagene Maraleucel Versus Chemotherapy in B-Cell Lymphoma: Interim Analysis of TRANSFORM Trial

Preliminary Study Data on Glofitamab Plus Polatuzumab Vedotin-piiq in DLBCL

CD19-Derived CAR Natural Killer Cell Therapy in Resistant B-Cell Lymphoma

Phase II Study Results of Lisocabtagene Maraleucel in Large B-Cell Lymphoma: From a Nonuniversity Setting

Aberrations of TP53 and Associated Outcomes With Immunotherapy for LBCL

New ROR1-Targeting Antibody-Drug Conjugate Under Study in Treatment of Lymphoid Cancers

Phase I Dose-Escalation Study of Mosunetuzumab in B-Cell Lymphomas

AACR 2022: Predicting Response/Resistance to Brexucabtagene Autoleucel in Mantle Cell Lymphoma

AACR 2022: Impact of PRMT5 Inhibition on BH3 Mimetic Sensitivity in Mantle Cell Lymphoma

AACR 2022: Can BCL2 Family Protein Dephosphorylation Resensitize Venetoclax-Induced Apoptosis?

AACR 2022: Pharmacologic Attributes of Axicabtagene Ciloleucel and Therapeutic Index in Lymphoma

Can ctDNA Analysis Be Used to Predict Outcomes in High-Risk DLBCL?

Phase II ZUMA-12 Trial Evaluates First-Line Use of Axicabtagene Ciloleucel in High-Risk LBCL

BTK Inhibitor Zanubrutinib Under Study in the Treatment of Resistant DLBCL

ASCO 2022: Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Follicular Lymphoma

ASCO 2022: Novel CAR T-Cell Therapy Targets CD20 in Treatment of B-Cell Malignancies

Phase III Study to Evaluate Tafasitamab-cxix–Based Therapy for Advanced B-Cell Lymphoma

Updated Trial Data on Tazemetostat-Based Regimen in Follicular Lymphoma

Axicabtagene Ciloleucel Outcomes in LBCL Stratified by Ethnicity and Race

Genetic and Molecular Profiling of Primary Mediastinal LBCL Identifies Probable Pathogenesis

SOHO 2022: Clinical Overview of CD20/CD3 Bispecific Antibodies in B-Cell Lymphoma

SOHO 2022: How Does CAR T-Cell Therapy Measure Up to ASCT in Advanced DLBCL?

ASTRO 2022: Salvage Radiotherapy for Advanced B-Cell NHL After CAR T-Cell Therapy

ASH 2022: Could IRF4 Become a Prognostic Marker in Follicular Lymphoma?

ASH 2022: POLARIX Trial Focuses on ctDNA for Risk Profiling in Diffuse Large B-Cell Lymphoma

ASH 2022: Can Ibrutinib Combination Replace ASCT for Some Younger Patients With Mantle Cell Lymphoma?

ASH 2022: Updated ELARA Trial Results of Tisagenlecleucel Therapy for Advanced Follicular Lymphoma

Adding Acalabrutinib to Combination Therapy for Mantle Cell Lymphoma

Long-Term Update on Upfront Rituximab Versus ‘Watch and Wait’ in Follicular Lymphoma

Final Analysis of Novel Triplet Combination in Resistant Follicular Lymphoma

Impact of Eligibility Criteria by Race/Ethnicity in First-Line Trials of DLBCL

Early-Phase Study of Combination BTK and PI3K Inhibition as B-Cell Lymphoma Therapy

Polatuzumab Vedotin-piiq–Based Therapy for Previously Untreated DLBCL: POLARIX Trial

Tisagenlecleucel Versus Standard of Care in Second-Line Therapy for Aggressive B-Cell Lymphomas

Evaluation of B-Cell Gene Signatures Using Immunomagnetic Cell Separation

Predictability of MCL1 and BCL2 Expression as Sensitivity Biomarkers in B-Cell Lymphomas

Axicabtagene Ciloleucel Versus Standard-of-Care Therapy for Resistant B-Cell Lymphoma

Prognostic Factors of Rheumatic Disease–Associated DLBCL

Polatuzumab Vedotin-piiq–Based Salvage Chemotherapy for DLBCL

Impact of FLI1 Expression Levels in Germinal Center–Derived DLBCL

Biomarkers and Pathways Associated With B-Cell Lymphoma

Immunogenicity Profile of Tisagenlecleucel in Diffuse Large B-Cell Lymphoma

First-Line Ibrutinib Plus Rituximab in Elderly Patients With Mantle Cell Lymphoma

Does the MYC/MYB/ZDHHC11 Network Impact the Growth of B-Cell Malignancies?

Risk of Breakthrough COVID Infection After Vaccination in Patients With Hematologic Malignancies

High-Risk Extranodal Marginal Zone Lymphoma: Novel Predictive Model Under Study

Does BTK Inhibitor Therapy Increase the Risk of HBV Reactivation in Those With Advanced DLBCL?

Could Zanubrutinib Be an Alternative to Patients With BTK Inhibitor–Intolerant B-Cell Malignancies?

Oral Azacitidine as Maintenance Therapy for Acute Myeloid Leukemia

Safety Profile of Midostaurin in Older Patients With AML

TCT 2021 JSP191 With Fludarabine and Total-Body Radiation in Older Adults With AML

Does Exposure to Occupational Pesticides Increase the Risk for AML

TCT 2021 CPX-351 Versus Chemotherapy for High-Risk of Secondary AML

TCT 2021 Natural Killer Cell Therapy Under Study in Selected Patients With AML

Is MRD Status Predictive of Survival in Resistant AML

Green Tea Treatment in Elderly Patients With Myelodysplasia-Related AML

Optimal Number of Chemotherapy Courses for Younger Patients With AML

AACR 2021: Daratumumab Plus Venetoclax Under Study in AML

Whole-Genome Sequencing for Genetic Profiling in Myeloid Cancers

Venetoclax-Based Therapy and Azole Antifungals in AML: Effects on Blood Cell Counts

ASCO 2021 Interim Analysis of Phase II Trial of Olutasidenib in IDH1-Mutant AML

ASCO 2021 Time-Limited Use of Aspacytarabine for Patients With AML Who Are Unfit for Chemotherapy

ASCO 2021 Early-Phase Results of Anti-CLL1–Based CAR T-Cell Therapy in Children With AML

ASCO 2021 Exploring the Molecular Architecture of Extramedullary AML

Novel Monoclonal Antibody and Chemotherapy Combination Under Study in Resistant AML

Early Results With Magrolimab Plus Azacitidine in AML

Adding Azacitidine to FLAG Chemotherapy in AML

Triplet Combination Therapies Under Study for IDH Mutated AML

Updated Overall Survival From QUAZAR AML-001 Trial of Oral Azacitidine in AML in First Remission

Impact of NPM1 and FLT3 Mutations on Prognosis in Patients With AML in Remission

Gilteritinib Versus Chemotherapy in Asian Patients With Resistant AML: Phase III Trial

Azacitidine Plus Ivosidenib in Patients With IDH1-Mutated AML: Global Phase III Trial

AACR 2022: Therapeutic Potential of Targeting CCRL2 in Secondary AML

Survival Trends in South Australia Suggest Better Therapies Needed for Older Patients With Leukemias

Phase III AGILE Trial: Combining Ivosidenib With Azacitidine in IDH1-Mutated AML

ASCO 2022: Potential Triplet Regimen Under Study in FLT3-ITD–Mutated AML

ASCO 2022: Phase II Study of Total Oral Triplet Regimen in Older Patients With AML

Induction Strategy and SCT Outcomes in Older Patients With AML

New Insights on Venetoclax Resistance in AML

Prognostic Value of MRD in Patients With Aggressive AML

Is Lenalidomide Effective in Pediatric Patients With Resistant AML

Second Cellular Therapy After Early Relapse of AML and Myelodysplastic Syndrome

Can Iron Chelation Improve Outcomes in AML When Combined With Cytarabine

Intracranial Hemorrhage in Patients Receiving Induction Chemotherapy for AML

Impact of AML Induction Chemotherapy on Blast Cell Survival and FOXM1 Activity

Significance of the SCP4-STK35/PDIK1L Complex in AML Pathogenesis

Association of Septic Shock and Mortality in Patients With AML

Diversity in Macrophage Function Among LC3-Associated Phagocytosis of AML Bone Marrow

Morbidity Burden of Blood or Marrow Transplantation Among AML Survivors

ASTRO 2020 Bladder-Sparing Radiochemotherapy Regimens Under Study

ASTRO 2020: Combination Radiotherapy and Durvalumab in Localized Bladder Cancer

SITC 2020 Tumor Mutation Burden and Response to Immunotherapy in Advanced Urothelial Cancer

ADP-A2M10 Dose-Escalation Trial in MAGE-A10–Positive Urothelial Tumors

Neoadjuvant Chemotherapy Deferral in Patients Undergoing Cystectomy for Bladder Cancer

Chronic Kidney Disease Risk Factor for Muscle-Invasive Bladder Cancer

Durvalumab-Based Combination Therapy in Non–Muscle Invasive Bladder Cancer

Proliposomal Paclitaxel in Non–Muscle Invasive Bladder Cancer Study Supports Move to Phase IIb

Does Biologic Sex Influence Progression of Bladder Cancer After BCG Treatment

Are There Racial Disparities in BCG Treatment of Non–Muscle Invasive Bladder Cancer

Adjuvant Durvalumab for Localized Urothelial Cancer

360 Hub

NCCN Resources